IDP-410: First direct N-MYC protein inhibitor delivers efficacy in intracraneal animal models bearing glioblastoma tumors.

important, news

IDP Pharma, in collaboration with Carlos III Research Institute (ISCIII) and Hospital 12 de Octubre in Madrid, has published a study in the journal Neurotherapeutics (https://link.springer.com/article/10.1007/s13311-021-01176-6) which reveals that a new experimental drug, IDP-410, directly engages the key oncoprotein N-MYC and reduces the growth of glioblastomas in animal models. The Company expects to develop further IDP-410 to bring a novel therapy to patients which currently lack treatment options.